The article is all about the anti -cancer drugs approved by the FDA for treating different forms of cancers. Article gives complete idea about each drug which was approved by FDA, which includes the use, route of administration, the dosing & the side effects.
Introduction
In 2016, the FDA has approved new drugs for different cancer types. Chemotherapy is one of the commonest tools which are used to treat cancer, and research continues in finding newer drugs and to find newer uses of existing drugs. The drugs aim precisely in identifying the cancerous cells and to reduce the effect on normal cells. Where in 60% of the patients who have received cabometyx required atleast reduction in one dose. 40% of the patients showed serious adverse reactions, which included abdominal pain, nausea, and diarrhoea 6, 7 .
Darzalex
Darzalex otherwise called as daratumumab (generic name) is used for treating multiple myeloma. Drug is manufactured by Janssen biotech 11 . This drug is administered as such and as well as in two combinations; one is along with lenalidomide & dexamethasone & the other is bortezomib & dexamethasone. If the drug is given along with lenalidomide and dexamethasone combination, the optimum dose to be given is 16 mg/kg. The drug is administered weekly for 1-8 weeks followed by a dosing frequency of 2 weeks for a period of 9-24 weeks, and then 4weeks for a period of 25 th week, until the patient shows progression 8, 9 . .The route of administration is an intravenous infusion on dilution. If the drug is given along with bortezomib and dexamethasone combination the dose to be administered is 16 mg/kg.
The frequency of administration is weekly for 1-9 weeks, followed by weekly thrice for 10-24 weeks, then 4weeks for 25 th week until progression. The rate of infusion is in range of 50-200 ml/ hour for a dilution volume of 500 and 1000 ml.
Increment in rate of infusion is 50 ml per every hour. During the increment in the infusion rates, two factors need to be taken into count that is the infusion reaction and severity of infusion 
Opidvo
Opidvo injection otherwise called as Nivolumab (Generic name).
Nivolumab is used to treat recurrent or metastatic head and neck squamous cell carcinoma with platinum based therapy 18,19. This drug is manufactured by Bristol-Myers Squibb Company.
The ideal dose to be administered is 3mg per kg for every conditions; it is stored at room temperature. .
Clinical assessments

Keytruda
Keytruda otherwise called as pembrolizumab (Generic name).
This is used for treating the patients suffering from metastatic non-small lung cancer whose tumors expressed high PD-L1
that is tumour proportion score is more than 50%. This is also 
Venclexta
Venclexta otherwise called as Venetoclax (Generic name). This drug is manufactured by Abbvie Company. This is used for treating patients suffering from chronic lymphocytic leukemia, who have undergone at least one anti -angiogenic therapy 25 .
The dose is administered on weekly basis , for first week the recommended dose is 20mg daily ,followed by for the second week it is 50 mg daily then 100mg daily for third week and for .
Clinical assessments
A multi-center, single-arm study was carried out in 136 patients who were given 250mg twice daily for a period of two weeks.
The response rate was reported to be 1on the basis of evaluation made by independent radiology review and by the investigators as well. Another trial was carried out involving 50 patients whose tumours were ROS1-positive by fluorescence using in situ hybridization or by reverse transcription polymerase chain reaction. The response was reported to be 66% as per independent radiology review and 72% as per investigators 36 .
Atezolizumab
Atezolizumab otherwise called as tecentriq is manufactured by
Genentech. This drug is used for treating patients suffering from metastatic non-small cell lung cancer, even after receiving the platinum containing chemotherapy. . Everolimus is a kinase inhibitor.
Clinical assessments
A multicenter, randomized, placebo-controlled clinical trial was carried out involving 302 patients suffering from neuroendocrine tumours of lung or GI origin. In this randomized trial 204 patients were made to receive everolimus and 203 patients received placebo along with supportive care in both the cases.
The progression free survival was reported to be 3.9months in case of everolimus received patients and 11months in placebo individuals 46 . .
Halaven injection
Clinical assessments
An open-label, randomized, multicenter, active controlled trial was carried out in 446 patients who were randomized in which 225 patients received eribulin and 225 patients received dacarbazine. The overall survival was reported to be 13.5 months in eribulin and 11.3 months in dacarbazine 50 .
Arzerra injection
Arzerra injection otherwise called as ofatumumab (generic name). This drug is manufactured by Galaxosmithekline. This drug is used for treating patients suffering from chronic lymphocytic leukemia. The optimum dose to be given to the patients is 300 mg on day 1 followed by 1000mg on day 8 after one week and 1000mg after 7 weeks and after that every 8 
